Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Global Hypersensitivity Therapeutics Report 2016: Pipeline Review of 57 Companies & 138 Molecules - Research and Markets

Research and Markets
Posted on: 27 Oct 16

Research and Markets has announced the addition of the "Hypersensitivity - Pipeline Review, H2 2016" report to their offering.

Hypersensitivity pipeline therapeutics constitutes close to 138 molecules. Out of which approximately 122 molecules are developed by Companies and remaining by the Universities

Institutes. The molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 1, 7, 15, 13, 56, 21 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 4, 1, 9 and 2 molecules, respectively.

Hypersensitivity - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Hypersensitivity, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Hypersensitivity and features dormant and discontinued projects.

Key Topics Covered:

  1. Introduction
  2. Hypersensitivity Overview
  3. Therapeutics Development
  4. Pipeline Products for Hypersensitivity - Overview
  5. Pipeline Products for Hypersensitivity - Comparative Analysis
  6. Hypersensitivity - Therapeutics under Development by Companies
  7. Hypersensitivity - Therapeutics under Investigation by Universities/Institutes
  8. Hypersensitivity Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Hypersensitivity - Products under Development by Companies
  13. Hypersensitivity - Products under Investigation by Universities/Institutes
  14. Hypersensitivity - Companies Involved in Therapeutics Development
  • Adamis Pharmaceuticals Corporation
  • Adverum Biotechnologies, Inc.
  • Aimmune Therapeutics, Inc.
  • Alfacyte Ltd
  • Allergopharma GmbH & Co. KG
  • Allergy Therapeutics Plc
  • Amgen Inc.
  • Anacor Pharmaceuticals, Inc.
  • AnaptysBio, Inc.
  • Anergis SA
  • Biotec Pharmacon ASA
  • Boehringer Ingelheim GmbH
  • Circassia Pharmaceuticals Plc
  • DBV Technologies S.A.
  • DNJ Pharma, Inc.
  • EA Pharma Co Ltd
  • Enzene Biosciences Ltd.
  • EpiVax, Inc.
  • Fountain Biopharma Inc.
  • HAL Allergy BV
  • Japan Tobacco Inc.
  • JW Pharmaceutical Corporation
  • Laboratorios LETI S.L.
  • Monosol Rx, LLC
  • NAL Pharmaceuticals Ltd.
  • Neovacs SA
  • Novartis AG
  • Ono Pharmaceutical Co., Ltd.
  • Regeneron Pharmaceuticals Inc
  • REGiMMUNE Corporation
  • Roxall Medizin GmbH
  • Sanofi
  • Toleranzia AB
  • United Biomedical, Inc.
  • United BioPharma, Inc.

For more information about this report visit http://www.researchandmarkets.com/research/7qjh39/hypersensitivity

View source version on businesswire.com: http://www.businesswire.com/news/home/20161027006189/en/

Business Wire
www.businesswire.com

Last updated on: 27/10/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.